$30M for Cancer-Focused TAE Life Sciences
HEALTHCARE: SPIN-OFF FROM FUSION COMPANY AIMING BIG
TAE LIFE SCIENCES
Investors & News
2020 | Market Watch
TAE Life Sciences Secures $30M in Initial B Round Phase to Accelerate Development of Unique Boron Delivery Drugs for Novel Cancer Treatment
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.
2019 | Cision PR Newswire
TAE Life Sciences Announces Scientific Advisory Board to Advance Cancer Research in Boron-Neutron Capture Therapy
BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas. BNCT uses the benign boron-10 isotope in a targeting drug that naturally embeds within fast-growing cancer cells, which then receive an intense, highly localized dose of radiation activated by a low-energy neutron beam.
2019 | PR Newswire
TAE Life Sciences Adds Seasoned Chief Operating Officer to Scale New Radiation Treatment Platform
Robert Hill brings expertise in the technical and clinical development of radiation systems to speed platform research and commercialization.
TLS in the News
Events
Tiny Yet Mighty: Nanotechnology in Radiation Therapy
Nanotechnology is the application of extremely small things—a nanometer is one billionth of a meter—used in science, engineering and technology. It involves the ability to view and control individual atoms and molecules and has been used in designing new therapeutics and diagnostics in medicine. As such, interest is mounting to harness nanotechnology’s potential to enhance radiation therapy and advance cancer care.
New TAE Unit Launched To Treat Cancers Gains $40M In Financing And Closes Partnership Deal
BNCT may provide a new option for patients with GBM and head and neck cancers due to its ability to leave healthy tissue unharmed.
TAE Life Sciences Inks $40M Series A Funding
TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.
TAE Life Sciences Raises $40M For Neutron Beam Cancer Treatment
TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.
TAE Raises $40M To Develop New Targeted Radiotherapy
Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.
$40 Million for Boron Neutron Capture Therapy
TAE Life Sciences aims to commercialize a cancer radiation treatment called Boron Neutron Capture Therapy. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells.
A Surprise Application To Cancer
There’s a radiological medical technique called Boron Neutron Capture Therapy (BNCT), which is like a very targeted chemotherapy.
TAE Life Sciences Is Trying To Make Boron Neutron Capture Therapy More Accessible
The neutron beam is aimed at the cancer patient’s tumors for about 30 minutes, and is combined with a boron-based substance that is injected into the patient intravenously and accumulates in the cancer cells.
TAE Life Sciences Announces $40 Million In Venture Capital
BNCT is a particularly promising technique for treating cancers of the head and neck region that are difficult or impossible to treat using other types of therapy. The procedure has already been tested in Japan, the United States and other locales.
TAE Life Sciences to Develop Groundbreaking Therapy for Difficult-to-Treat Cancers, including Head, Neck and GBM; Announces $40 Million Series A Funding
TAE Life Sciences is the first to license TAE Technologies’ accelerator-based neutron beam technology for clinical investigation of Boron Neutron Capture Therapy (BNCT).
International Society for Neutron Capture Therapy (ISNCT)
September 13-18, 2020
Granada, Spain
JASTRO 2020
October 1-3, 2020
Sapporo, Japan
ASTRO Annual Meeting 2020
October 25-28, 2020
Miami Beach, FL